- Trial phase
- Filed/BLA-stage (Phase 1/2 registrational study completed)
- Time to market
- Potential FDA accelerated approval and commercial launch in 2027 if the BLA submission is completed in Q4 2026 and the FDA grants a standard or priority review timeline.
- Why 6/10
- The next hard catalyst is completion of the rolling BLA submission to the FDA, expected in Q4 2026 (by December 31, 2026). This is a near-term milestone for a BLA-stage asset that PTC just acquired for $111M, but it is a submission completion, not a regulatory decision. PTC has a diversified revenue base (Sephience, Translarna, Emflaza) so ST-920 is not a single-asset binary, capping the score at 6.
Watch for completion of the rolling BLA submission to the FDA in Q4 2026 (by Dec 31). If submitted on time, the FDA will set a PDUFA date, likely in H2 2027, which would be the next major binary catalyst. Any delay in the BLA submission would be a negative signal. Also monitor the WORLD Symposium in February 2027 for updated clinical data.
Price Chart
Executive Summary
ST-920 (isaralgagene civaparvovec) is a one-time AAV gene therapy for Fabry disease that PTC Therapeutics (PTCT) acquired from bankrupt Sangamo Therapeutics in September 2026 for $111M upfront plus up to $100M in milestones. A rolling BLA submission to the FDA for accelerated approval is expected to be completed in Q4 2026, with potential commercial launch in 2027. The Phase 1/2 STAAR study showed a positive mean annualized eGFR slope of +1.965 at 52 weeks (renal function improvement) and a favorable safety profile, and the FDA agreed this endpoint can serve as the primary basis for accelerated approval. PTC has a strong commercial infrastructure and $2.13B in cash to support a launch. The Fabry disease treatment market is approximately $2.5B and growing.
How It Works
ST-920 is a one-time gene therapy given as an intravenous infusion. It uses a harmless virus (AAV2/6) to deliver a working copy of the GLA gene into liver cells. The liver then produces the missing alpha-galactosidase A enzyme that Fabry disease patients lack, and releases it into the bloodstream. This is designed to provide a permanent or long-lasting source of the enzyme, eliminating the need for regular enzyme replacement infusions.
Trial Status
The registrational Phase 1/2 STAAR study (NCT04046224) has completed enrollment with 36 patients. Positive topline results were announced in June 2025, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 dosed patients. Detailed data presented in September 2025 and February 2026 showed sustained kidney function improvement and stable cardiac function. A rolling BLA submission was initiated by Sangamo in December 2025 and is expected to be completed by PTC in Q4 2026. A long-term follow-up study is ongoing.
The Two-Sided Case
Upcoming Catalysts
- Completion of rolling BLA submission to FDA in Q4 2026 (by December 31, 2026)
- FDA acceptance of BLA and PDUFA date assignment (likely H1 2027)
- Potential FDA Advisory Committee meeting for ST-920
- WORLD Symposium February 2027 for updated clinical data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report